Xeltis’ vascular access graft, aXess, recently demonstrated strong efficacy in an EU pivotal trial in patients with end-stage ...

Topline data show the Factor XIa inhibitor asundexian lowers recurrent stroke risk vs placebo with no increase in major bleeding events.

Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...